Figure 7
From: A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma
Immunohistochemical staining of PDAC-X2 cells, xenografted tumour and primary tumour. (A1), (B1) and (C1) CK7-positive staining in PDAC-X2 cells (A1), xenografted tumour (B1) and primary tumour (C1). (A2), (B2) and (C2): CK19-positive staining in PDAC-X2 cells (A2), xenografted tumour (B2) and primary tumour (C2). (A3), (B3) and (C3): Quantitative analysis showed a 40% positive rate of Ki-67 in PDAC-X2 cells (A3), xenografted tumour (B3) and primary tumour (C3). (A4), (B4) and (C4): E-cadherin-positive staining in PDAC-X2 cells (A4), xenografted tumour (B4) and primary tumour (C4). (A5), (B5) and (C5): Vimentin-positive staining in PDAC-X2 cells (A5), xenografted tumour (B5) and primary tumour (C5). (A6), (B6) and (C6): CEA-positive staining in PDAC-X2 cells (A6), xenografted tumour (B6) and primary tumour (C6). (A7), (B7) and (C7): CA19-9-positive staining in PDAC-X2 cells (A7), xenografted tumour (B7) and primary tumour (C7). (scale bar = 50 μm).
